Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Eye Disease in Behçet Syndrome

  • Chapter
  • First Online:
Behçet Syndrome

  • 789 Accesses

Abstract

Ocular involvement is the main cause of morbidity in Behçet syndrome (BS). While the overall frequency is ∼50%, the young males have ∼70%, while the older females have ∼20% chance of acquiring eye disease. It starts within the first few years of the disease, involves both eyes in the majority of the patients, and runs a more severe course in males. It is a nongranulomatous panuveitis and retinal vasculitis that has a periodic course characterized by activations and remissions. Impairment or blurring of vision, redness, and ocular discomfort are the main symptoms during an attack which usually subsides within a few weeks. Cellular infiltration within the anterior chamber is a common presenting sign. It can be accompanied by exudation of protein from the inflamed iris vessels. When the cellular infiltrate and fibrinous deposits are extensive, a hypopyon is formed due to gravity. Recurrent inflammatory activity in the anterior chamber may lead to anterior and posterior synechiae, secondary glaucoma, and cataract. Vitreal inflammatory signs in the form of haze and cells are the main inflammatory findings of posterior segment involvement. Occlusive retinal vasculitis, which is the hallmark of ocular disease of BS, almost always accompanies posterior segment involvement. During activations, funduscopic examination may show vitreal deposits, retinal infiltrates, retinal edema, hemorrhages, and macular edema. In advanced stages, the visual loss becomes permanent and sheathing of blood vessels, ghost vessels, atrophic and pigmentary macular changes, and optic atrophy are seen. Visual prognosis of BS has dramatically improved in the last two to three decades by better use of conventional immunosuppressives such as cyclosporine and azathioprine and more recently biologics like anti-TNF alpha agents and interferon alpha. Ophthalmic surgery for secondary cataract and glaucoma as well as for vitreoretinal complications has also become much more successful.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. N Engl J Med. 1999;341:1284–91.

    Article  CAS  PubMed  Google Scholar 

  2. Yazici H, Tüzün Y, Pazarli H, et al. Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behçet’s syndrome. Ann Rheum Dis. 1984;43:783–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Yalçındağ FN, Özdal PC, Özyazgan Y, et al. Demographic and clinical characteristics of uveitis in Turkey: The First National Registry Report. Ocul Immunol Inflamm. 2018;26:17–26.

    Article  PubMed  Google Scholar 

  4. Mishima S, Masuda K, Izawa Y, et al. Behçet’s disease in Japan: ophthalmologic aspects. Trans Am Ophthalmol Soc. 1979;76:225–79.

    Google Scholar 

  5. Goto H, Mochizuki M, Yamaki K, et al. Epidemiological survey of intraocular inflammation in Japan. Jpn J Ophthalmol. 2007;51:41–4.

    Article  PubMed  Google Scholar 

  6. Rodriguez A, Calonge M, Pedroza-Serez M, et al. Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol. 1996;114:593–9.

    Article  CAS  PubMed  Google Scholar 

  7. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet’s syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine. 2003;82:60–76.

    Article  PubMed  Google Scholar 

  8. Tugal-Tutkun I, Onal S, Altan Yaycıoglu R, et al. Uveitis in Behçet’s disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138:373–80.

    Article  PubMed  Google Scholar 

  9. Tunc R, Keyman E, Melikoglu M, Fresko I, Yazici H. Target organ associations in Turkish patients with Behçet’s disease: a cross sectional study with exploratory factor analysis. J Rheumatol. 2002;29:2393–6.

    PubMed  Google Scholar 

  10. Nussenblatt RB, Whitcup SM, Paletsine AG. Behçet’s disease. In: Nussenblatt RB, Whitcup SM, Paletsine AG, editors. Uveitis: fundamentals and clinical practice. Philadelphia: Mosby; 2004. p. 350–71.

    Google Scholar 

  11. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–16.

    Article  PubMed  Google Scholar 

  12. George RK, Chan CC, Whitcup SM, et al. Ocular immunopathology of Behçet’s disease. Surv Ophthalmol. 1997;42:157–62.

    Article  CAS  PubMed  Google Scholar 

  13. Ramsay A, Lightman S. Hypopyon uveitis. Surv Ophthalmol. 2001;46:1–18.

    Article  CAS  PubMed  Google Scholar 

  14. Pazarlı H, Ozyazgan Y, Aktunc T. Clinical observations on hypopyon attacks of Behçet’s disease in Turkey. In: Seventh international conference on Behçet’s disease (abstracts), Rochester, MN, 14–15 Sept 1989.

    Google Scholar 

  15. Tugal-Tutkun I, Urgancioglu M, Foster CS. Immunopathologic study of the conjunctiva in patients with Behçet’s disease. Ophthalmology. 1995;102:1660–8.

    Article  CAS  PubMed  Google Scholar 

  16. Zamir E, Bodaghi B, Tugal-Tutkun I, et al. Conjunctival ulcers in Behçet’s disease. Ophthalmology. 2003;110:1137–41.

    Article  PubMed  Google Scholar 

  17. Elgin U, Berker N, Batman A. Incidence of secondary glaucoma in Behçet’s disease. J Glaucoma. 2004;13:441–4.

    Article  PubMed  Google Scholar 

  18. Yalvaç IS, Sungur G, Turhan E, et al. Trabeculectomy with mitomycin-C in uveitic glaucoma associated with Behçet’s disease. J Glaucoma. 2004;13:450–3.

    Article  PubMed  Google Scholar 

  19. Baer JC, Raizman MB, Foster CS. Ocular Behçet’s disease in the United States: clinical presentation and visual outcome in 29 patients. In: Masahiko U, Shigeaki O, Koki A, editors. Proceedings of the 5th international symposium on the immunology and immunopathology of the eye, Tokyo. New York: Elsevier Science; 1990. p. 383.

    Google Scholar 

  20. Ehrlich GE. Vasculitis in Behçet’s disease. Int Rev Immunol. 1997;14:81–8.

    Article  CAS  PubMed  Google Scholar 

  21. Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. The Neuro-Behçet’s Study Group. Brain. 1999;122:2171–82.

    Article  PubMed  Google Scholar 

  22. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Neovascularization of the optic disc in Behçet’s disease. Jpn J Ophthalmol. 2006;50:256–65.

    Article  PubMed  Google Scholar 

  23. Foster CS, Vitale AT. Adamantiades-Behçet’s disease. In: Foster CS, Vitale AT, editors. Diagnosis and treatment of uveitis. Philadelphia: W.B. Saunders; 2002. p. 632–52.

    Google Scholar 

  24. Kacmaz RO, Kempen JH, Newcomb C, Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Group, et al. Ocular inflammation in Behçet’s disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol. 2008;146:828–36.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Tugal-Tutkun I, Ozdal PC, Oray M, Onal S. Review for diagnostics of the year: multimodal imaging in Behçet uveitis. Ocul Immunol Inflamm. 2017;25:7–19.

    Article  PubMed  Google Scholar 

  26. Atmaca LS. Fundus changes associated with Behçet’s disease. Graefes Arch Clin Exp Ophthalmol. 1989;227:340–4.

    Article  CAS  PubMed  Google Scholar 

  27. Mesquida M, Llorenç V, Fontenla JR, et al. Use of ultrawide-field retinal imaging in the management of active Behçet retinal vasculitis. Retina. 2014;34:2121–7.

    Article  PubMed  Google Scholar 

  28. Bozzoni-Pantaleoni F, Gharbiya M, Pirraglia MP, et al. Indocyanine green angiographic findings in Behçet’s disease. Retina. 2001;21:230–6.

    Article  CAS  PubMed  Google Scholar 

  29. Atmaca LS, Sönmez PA. Fluorescein and indocyanine green angiography findings in Behçet’s disease. Br J Ophthalmol. 2003;87:1466–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Gedik S, Akova YA, Yılmaz G, et al. Indocyanine green and fundus fluorescein angiographic findings in patients with active ocular Behçet’s disease. Ocul Immunol Inflamm. 2005;13:51–8.

    Article  PubMed  Google Scholar 

  31. Onal S, Uludag G, Oray M, et al. Quantitative analysis of structural alterations in the choroid of patients with active Behçet uveitis. Retina. 2018;38:828–40.

    Article  PubMed  Google Scholar 

  32. Yesilirmak N, Lee WH, Gur Gungor S, et al. Enhanced depth imaging optical coherence tomography in patients with different phases of Behcet’s panuveitis. Can J Ophthalmol. 2017;52:48–53.

    Article  PubMed  Google Scholar 

  33. Khairallah M, Abroug N, Khochtali S, et al. Optical coherence tomography angiography in patients with Behçet uveitis. Retina. 2017;37:1678–91.

    Article  PubMed  Google Scholar 

  34. Somkijrungroj T, Vongkulsiri S, Kongwattananon W, et al. Assessment of vascular change using swept-source optical coherence tomography angiography: a new theory explains central visual loss in Behcet’s disease. J Ophthalmol. 2017;2017:2180723.

    PubMed  PubMed Central  Google Scholar 

  35. Winter FC, Yukins RE. The ocular pathology of Behçet’s disease. Am J Ophthalmol. 1966;62:257–62.

    Article  CAS  PubMed  Google Scholar 

  36. Mullaney J, Collum LM. Ocular vasculitis in Behçet’s disease: a pathological and immunohistochemical study. Int Ophthalmol. 1985;7:183–91.

    Article  CAS  PubMed  Google Scholar 

  37. Hegab S, Al-Mutawa S. Immunopathogenesis of Behçet’s disease. Clin Immunol. 2000;96:174–86.

    Article  CAS  PubMed  Google Scholar 

  38. Atmaca LS, Batioglu F, Idil A. Retinal and disc neovascularization in Behçet’s disease and efficacy of laser photocoagulation. Graefes Arch Clin Exp Ophthalmol. 1996;234:94–9.

    Article  CAS  PubMed  Google Scholar 

  39. El Belhadji M, Hamdani M, Laouissi N, et al. L’attente ophthalmologique dans la maladie d Behçet: a propos de 520 cas. J Fr Ophthalmol. 1997;20:592–8.

    Google Scholar 

  40. Ando K, Fujino Y, Hijikata K, et al. Epidemiological features and visual prognosis of visual prognosis of Behçet’s disease. Jpn J Ophthalmol. 1999;43:312–7.

    Article  CAS  PubMed  Google Scholar 

  41. Sakamoto M, Akazawa K, Nishioka Y, et al. Prognostic factors of vision in patients with Behçet’s disease. Ophthalmology. 1995;102:317–21.

    Article  CAS  PubMed  Google Scholar 

  42. Nussenblatt RB, Pelestine AG, Chan CC, et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467–71.

    Article  CAS  PubMed  Google Scholar 

  43. Davis JL, Madow B, Cornett J, et al. Scale for photographic grading of vitreous haze in uveitis. Am J Ophthalmol. 2010;150:637–41.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Tugal-Tutkun I, Cingu K, Kir N, et al. Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behçet’s uveitis. Graefes Arch Clin Exp Ophthalmol. 2008;246:1169–77.

    Article  PubMed  Google Scholar 

  45. Kaburaki T, Namba K, Sonoda KH, et al. Behcet’s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol. 2014;58:120–30.

    Article  CAS  PubMed  Google Scholar 

  46. Yalcindag FN, Bingol Kiziltunc P, Savku E. Evaluation of intraocular inflammation with laser flare photometry in Behçet uveitis. Ocul Immunol Inflamm. 2017;25:41–5.

    Article  PubMed  Google Scholar 

  47. Hatemi G, Silman A, Bang D, et al. Management of Behçet’s disease: a systematic literature review for the EULAR evidence based recommendations for the management of Behçet’s disease. Ann Rheum Dis. 2008;68:1528–34.

    Article  PubMed  CAS  Google Scholar 

  48. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785–96.

    Article  PubMed  Google Scholar 

  49. Onal S, Tugal-Tutkun I. Re: Levy-Clarke et al.: Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders (Ophthalmology 2014;121:785–96). Ophthalmology. 2014;121(10):e57–8.

    Article  PubMed  Google Scholar 

  50. Palestine AG, Kolfenbach JR, Ozzello DJ. Rheumatologists and ophthalmologists differ in treatment decisions for ocular Behçet disease. J Clin Rheumatol. 2016;22:316–9.

    Article  PubMed  Google Scholar 

  51. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77:808.

    PubMed  Google Scholar 

  52. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med. 1990;322:281–5.

    Article  CAS  PubMed  Google Scholar 

  53. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behçet’s syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40:769–74.

    Article  CAS  PubMed  Google Scholar 

  54. BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behçet’s syndrome. Transplant Proc. 1988;20(3 Suppl 4):136–43.

    CAS  PubMed  Google Scholar 

  55. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet. 1989;1:1093–6.

    Article  CAS  PubMed  Google Scholar 

  56. Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet’s syndrome: a single masked trial. Br J Ophthalmol. 1992;76:241–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Akman-Demir G, Ayranci O, Kurtuncu M, et al. Cyclosporine for Behçet’s uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol. 2008;26(Suppl 50):S84–90.

    CAS  PubMed  Google Scholar 

  58. Durand JM, Soubeyrand J. Interferon-alpha 2b for refractory ocular Behçet’s disease. Lancet. 1994;344:333.

    Article  CAS  PubMed  Google Scholar 

  59. Feron EJ, Rothova A, van Hagen PM, Baarsma GS, Suttorp-Schulten MS. Interferon-alpha 2b for refractory ocular Behçet’s disease. Lancet. 1994;343:1428.

    Article  CAS  PubMed  Google Scholar 

  60. Kötter I, Eckstein AK, Stübiger N, Zierhut M. Treatment of ocular symptoms of Behçet’s disease with interferon alpha 2a: a pilot study. Br J Ophthalmol. 1998;82:488–94.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Kötter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423–31.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91:335–9.

    Article  PubMed  Google Scholar 

  63. Krause L, Turnbull JR, Torun N, et al. Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet’s disease. Adv Exp Med Biol. 2003;528:511–9.

    Article  CAS  PubMed  Google Scholar 

  64. Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet’s uveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244:1692–5.

    Article  CAS  PubMed  Google Scholar 

  65. Yang P, Huang G, Du L, et al. Long-term efficacy and safety of interferon alpha-2a in the treatment of Chinese patients with Behçet’s uveitis not responding to conventional therapy. Ocul Immunol Inflamm. 2019;27:7–14.

    Article  PubMed  CAS  Google Scholar 

  66. Shi J, Zhao C, Zhou J, et al. Effectiveness and safety of interferon a2a as an add-on treatment for refractory Behçet’s uveitis. Ther Adv Chronic Dis. 2019;10:1–9.

    Article  Google Scholar 

  67. Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet’s disease. Am J Ophthalmol. 2008;146:837–44.e1.

    Article  CAS  PubMed  Google Scholar 

  68. Sobaci G, Erdem U, Durukan AH, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet’s uveitis refractory to conventional treatments. Ophthalmology. 2010;117:1430–5.

    Article  PubMed  Google Scholar 

  69. Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol. 2011;129:288–94.

    Article  CAS  PubMed  Google Scholar 

  70. Deuter CME, Zierhut M, Mohle A, et al. Long-term remission after cessation of interferon-a treatment in patients with severe uveitis due to Behçet’s disease. Arthritis Rheum. 2010;62:2796–805.

    Article  CAS  PubMed  Google Scholar 

  71. Diwo E, Gueudry J, Saadoun D, et al. Long-term efficacy of interferon in severe uveitis associated with Behçet disease. Ocul Immunol Inflamm. 2017;25:76–84.

    Article  CAS  PubMed  Google Scholar 

  72. Keskin Y, Seyahi E, Poyraz C, et al. Interferon alfa-associated depression in patients with Behçet’s syndrome: a prospective controlled study. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S175.

    PubMed  Google Scholar 

  73. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet. 2001;358:295–6.

    Article  CAS  PubMed  Google Scholar 

  74. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial. Arthritis Rheum. 2005;52:2478–84.

    Article  CAS  PubMed  Google Scholar 

  75. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet’s disease. Ann Intern Med. 2004;140:404–6.

    Article  CAS  PubMed  Google Scholar 

  76. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–8.

    CAS  PubMed  Google Scholar 

  77. Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Behçet’s Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet’s disease. Arch Ophthalmol. 2012;130:592–8.

    Article  CAS  PubMed  Google Scholar 

  78. Abu El-Asrar AM, Abboud EB, Aldibhi H, et al. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet’s disease. Int Ophthalmol. 2005;26:83–92.

    Article  PubMed  Google Scholar 

  79. Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet’s disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46:1161–4.

    Article  CAS  Google Scholar 

  80. Bodaghi B, Bui Quoc E, Wechsler B, et al. Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis. 2005;64:962–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet’s disease. Am J Ophthalmol. 2008;146:845.e1–50.e1.

    Google Scholar 

  82. Capella MJ, Foster CS. Long-term efficacy and safety of infliximab in the treatment of Behçet’s disease. Ocul Immunol Inflamm. 2012;20:198–202.

    Article  CAS  PubMed  Google Scholar 

  83. Takeuchi M, Asukata Y, Kawagoe T, et al. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behcet’s disease. Ocul Immunol Inflamm. 2012;20:193–7.

    Article  CAS  PubMed  Google Scholar 

  84. Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behçet’s disease on infliximab therapy. Br J Ophthalmol. 2011;95:1245–50.

    Article  PubMed  Google Scholar 

  85. Guzelant G, Ucar D, Esatoglu SN, et al. Infliximab for uveitis of Behçet’s syndrome: a trend for earlier initiation. Clin Exp Rheumatol. 2017;35 Suppl 108(6):86–9.

    PubMed  Google Scholar 

  86. Fabiani C, Sota J, Vitale A, et al. Ten-year retention rate of infliximab in patients with Behçet’s disease-related uveitis. Ocul Immunol Inflamm. 2019;27:34–9. https://doi.org/10.1080/09273948.2017.1391297.

    Article  PubMed  Google Scholar 

  87. Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm. 2010;18:226–32.

    Article  CAS  PubMed  Google Scholar 

  88. Fabiani C, Vitale A, Emmi G, et al. Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36:183–9.

    Article  PubMed  Google Scholar 

  89. Fabiani C, Sota J, Vitale A, et al. Cumulative retention rate of adalimumab in patients with Behçet’s disease-related uveitis: a four-year follow-up study. Br J Ophthalmol. 2018;102:637–41.

    Article  PubMed  Google Scholar 

  90. Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375:932–43.

    Article  CAS  PubMed  Google Scholar 

  91. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183–92.

    Article  CAS  PubMed  Google Scholar 

  92. Fabiani C, Sota J, Rigante D, et al. Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Behçet’s disease. Ocul Immunol Inflamm. 2019;27:58–63. https://doi.org/10.1080/09273948.2017.1351573.

    Article  CAS  PubMed  Google Scholar 

  93. Llorenç V, Mesquida M, Sainz de la Maza M, et al. Certolizumab Pegol, a new anti-TNF-αin the armamentarium against ocular inflammation. Ocul Immunol Inflamm. 2016;24:167–72.

    PubMed  Google Scholar 

  94. Lopalco G, Emmi G, Gentileschi S, et al. Certolizumab Pegol treatment in Behcet’s disease with different organ involvement: a multicenter retrospective observational study. Mod Rheumatol. 2017;27:1031–5.

    Article  CAS  PubMed  Google Scholar 

  95. Atienza-Mateo B, Calvo-Río V, Beltrán E, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet’s disease: multicentre retrospective study. Rheumatology (Oxford). 2018;57:856–64.

    Article  CAS  Google Scholar 

  96. Eser Ozturk H, Oray M, Tugal-Tutkun I. Tocilizumab for the treatment of Behçet uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy. Ocul Immunol Inflamm. 2018;26:1005–14.

    Article  CAS  PubMed  Google Scholar 

  97. Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol. 2015;34:1293–301.

    Article  PubMed  Google Scholar 

  98. Fabiani C, Vitale A, Emmi G, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36:191–7.

    Article  PubMed  Google Scholar 

  99. Tugal-Tutkun I, Pavesio C, De Cordoue A, et al. Use of gevokizumab in patients with Behçet’s disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study. Ocul Immunol Inflamm. 2018;26:1023–33.

    Article  CAS  PubMed  Google Scholar 

  100. Gül A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis. 2012;71:563–6.

    Article  PubMed  CAS  Google Scholar 

  101. Tugal-Tutkun I, Kadayifcilar S, Khairallah M, et al. Safety and efficacy of gevokizumab in patients with Behçet’s disease uveitis: results of an exploratory phase 2 study. Ocul Immunol Inflamm. 2017;25:62–70.

    Article  CAS  Google Scholar 

  102. Buggage RR, Levy-Clarke G, Sen HN, et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet’s disease. Ocul Immunol Inflamm. 2007;15:63–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120:777–87.

    Article  PubMed  Google Scholar 

  104. Tuncer S, Yilmaz S, Urgancioglu M, Tugal-Tutkun I. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet’s disease. J Ocul Pharmacol Ther. 2007;23:395–401.

    Article  CAS  PubMed  Google Scholar 

  105. Park UC, Park JH, Yu HG. Long-term outcome of intravitreal triamcinolone acetonide injection for the treatment of uveitis attacks in Behçet disease. Ocul Immunol Inflamm. 2014;22:27–33.

    Article  CAS  PubMed  Google Scholar 

  106. Atmaca LS, Yalcindag FN, Ozdemir O. Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behçet’s disease. Graefes Arch Clin Exp Ophthalmol. 2007;245:451–6.

    Article  CAS  PubMed  Google Scholar 

  107. Karacorlu M, Mudun B, Ozdemir H, Karacorlu SA, Burumcek E. Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behçet’s disease. Am J Ophthalmol. 2004;138:289–91.

    Article  CAS  PubMed  Google Scholar 

  108. Ohguro N, Yamanaka E, Otori Y, Saishin Y, Tano Y. Repeated intravitreal triamcinolone injections in Behçet’s disease that is resistant to conventional therapy: one-year results. Am J Ophthalmol. 2006;141:218–20.

    Article  CAS  PubMed  Google Scholar 

  109. Tugal-Tutkun I, Araz B, Cagatay A. CMV retinitis after intravitreal triamcinolone acetonide injection in a patient with Behçet’s uveitis. Int Ophthalmol. 2010;30:591–3.

    Article  PubMed  Google Scholar 

  110. Coşkun E, Celemler P, Kimyon G, et al. Intravitreal dexamethasone implant for treatment of refractory Behçet posterior uveitis: one-year follow-up results. Ocul Immunol Inflamm. 2015;23:437–43.

    Article  PubMed  CAS  Google Scholar 

  111. Fabiani C, Emmi G, Lopalco G, et al. Intravitreal dexamethasone implant as an adjunct weapon for severe and refractory uveitis in Behçet’s disease. Isr Med Assoc J. 2017;19:415–9.

    PubMed  Google Scholar 

  112. Oh EK, Lee EK, Yu HG. Long-term results of fluocinolone acetonide intravitreal implant in Behçet intractable posterior uveitis. Can J Ophthalmol. 2014;49:273–8.

    Article  PubMed  Google Scholar 

  113. Sangwan VS, Pearson PA, Paul H, Comstock TL. Use of the fluocinolone acetonide intravitreal implant for the treatment of noninfectious posterior uveitis: 3-year results of a randomized clinical trial in a predominantly Asian population. Ophthalmol Ther. 2015;4:1–19.

    Article  PubMed  Google Scholar 

  114. Mirshahi A, Namavari A, Djalilian A, et al. Intravitreal bevacizumab (Avastin) for the treatment of cystoid macular edema in Behçet’s disease. Ocul Immunol Inflamm. 2009;17:59–64.

    Article  PubMed  Google Scholar 

  115. Ghassemi F, Mirak SA, Chams H, et al. Characteristics of macular edema in Behcet disease after intravitreal bevacizumab injection. J Ophthalmic Vis Res. 2017;12:44–52.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Markomichelakis NN, Aissopou EK, Maselos S, et al. Biologic treatment options for retinal neovascularization in Behçet’s disease. Ocul Immunol Inflamm. 2019;27:51–7. https://doi.org/10.1080/09273948.2017.1332228.

    Article  CAS  PubMed  Google Scholar 

  117. Hu K, Lei B, Kijlstra A, Li P, et al. Male sex, erythema nodosum, and electroretinography as predictors of visual prognosis after cataract surgery in patients with Behçet disease. J Cataract Refract Surg. 2012;38:1382–8.

    Article  PubMed  Google Scholar 

  118. Berker N, Soykan E, Elgin U, Ozkan SS. Phacoemulsification cataract extraction and intraocular lens implantation in patients with Behçet’s disease. Ophthalmic Surg Lasers Imaging. 2004;35:215–8.

    Article  PubMed  Google Scholar 

  119. Krause L, Altenburg A, Bechrakis NE, et al. Intraocular surgery under systemic interferon-alpha therapy in ocular Adamantiades-Behçet’s disease. Graefes Arch Clin Exp Ophthalmol. 2007;245:1617–21.

    Article  PubMed  Google Scholar 

  120. Alfawaz A, Alrashidi S, Kalantan H, et al. Cataract surgery under systemic infliximab therapy in patients with refractory uveitis associated with Behcet disease. Ann Saudi Med. 2014;34:328–33.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Nishida T, Shibuya E, Asukata Y, et al. Clinical course before and after cataract and glaucoma surgery under systemic infliximab therapy in patients with Behçet’s disease. Case Rep Ophthalmol. 2011;2:189–92.

    Article  PubMed  PubMed Central  Google Scholar 

  122. Fan F, Jia Z, Li K, Zhao X, Ma Q. Cataract surgery combined with micro-incision vitrectomy in patients with Behcet’s disease uveitis. BMC Ophthalmol. 2018;18:158.

    Article  PubMed  PubMed Central  Google Scholar 

  123. Komae K, Takamoto M, Tanaka R, et al. Initial trabeculectomy with mitomycin-c for secondary glaucoma-associated with uveitis in Behçet disease patients. J Glaucoma. 2017;26:603–7.

    Article  PubMed  Google Scholar 

  124. Elgin U, Berker N, Batman A, Soykan E. Trabeculectomy with mitomycin C in secondary glaucoma associated with Behçet’s disease. J Glaucoma. 2007;16:68–72.

    Article  PubMed  Google Scholar 

  125. Mesquida M, Pelegrín L, Llorenç V, et al. Pars plana vitrectomy for vitreoretinal complications of Behçet uveitis. Eur J Ophthalmol. 2013;23:119–28.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

    Yılmaz Özyazgan

  2. Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

    Ilknur Tugal-Tutkun

Authors
  1. Yılmaz Özyazgan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ilknur Tugal-Tutkun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yılmaz Özyazgan .

Editor information

Editors and Affiliations

  1. School of Medicine, New York University, New York, NY, USA

    Yusuf Yazici

  2. Department of Internal Medicine, Istanbul University, Istanbul, Turkey

    Gulen Hatemi

  3. Department of Rheumatology, Istanbul University, Istanbul, Turkey

    Emire Seyahi

  4. Department of Medicine, Academic Hospital, Istanbul, Turkey

    Hasan Yazici

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Özyazgan, Y., Tugal-Tutkun, I. (2020). Eye Disease in Behçet Syndrome. In: Yazici, Y., Hatemi, G., Seyahi, E., Yazici, H. (eds) Behçet Syndrome. Springer, Cham. https://doi.org/10.1007/978-3-030-24131-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-24131-5_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-24130-8

  • Online ISBN: 978-3-030-24131-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation